It may be that production of IFNγ by Tregs in the systemic lymphoid compartment, tumor-draining lymph nodes, or tertiary lymphoid organs triggers more potent effects on antitumor immunity than production of IFNγ by Tregs in the tumor itself, promoting FS120m therapeutic efficacy. Here, IFNG is linked to neoplasm.